thalidomide and Myeloproliferative-Myelodisplastic Diseases studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"Primary myelofibrosis (PMF) and overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal hematopoietic disorders that share similar clinical features and molecular abnormalities, such as the Janus kinase 2 (JAK2) valine to phenylalanine mutation at codon 617 (V617F) and the tet methylcytosine dioxygenase 2 (TET2) mutation."	6.77	A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). ( Advani, A; Bejanyan, N; Chan, J; Jankowska, A; Kalaycio, M; Maciejewski, JP; Mooney, L; Raza, A; Saunthararajah, Y; Sekeres, MA; Tiu, RV, 2012)
"Primary myelofibrosis (PMF) and overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal hematopoietic disorders that share similar clinical features and molecular abnormalities, such as the Janus kinase 2 (JAK2) valine to phenylalanine mutation at codon 617 (V617F) and the tet methylcytosine dioxygenase 2 (TET2) mutation."	2.77	A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). ( Advani, A; Bejanyan, N; Chan, J; Jankowska, A; Kalaycio, M; Maciejewski, JP; Mooney, L; Raza, A; Saunthararajah, Y; Sekeres, MA; Tiu, RV, 2012)
"Ranimustine was therefore administered starting in July 2011 to control the blood cell count, but the rash associated with Sweet's syndrome persisted."	1.40	Successful treatment of an essential thrombocythemia patient complicated by Sweet's syndrome with combination of chemotherapy and lenalidomide. ( Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nagashima, K; Sakurai, T; Sato, M; Yamada, M; Yoshida, M, 2014)

Research

Studies (2)

Authors

Trials

1 trial available for thalidomide and Myeloproliferative-Myelodisplastic Diseases

Other Studies

1 other study available for thalidomide and Myeloproliferative-Myelodisplastic Diseases

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Yamada, M	1
Kuroda, H	1
Yoshida, M	1
Jomen, W	1
Abe, T	1
Sakurai, T	1
Fujii, S	1
Maeda, M	1
Fujita, M	1
Nagashima, K	1
Matsuno, T	1
Sato, M	1
Kato, J	1
Bejanyan, N	1
Tiu, RV	1
Raza, A	1
Jankowska, A	1
Kalaycio, M	1
Advani, A	1
Chan, J	1
Saunthararajah, Y	1
Mooney, L	1
Maciejewski, JP	1
Sekeres, MA	1